Tag: Zydus
Zydus plans to launch innovative Semaglutide Injection in India on Day...
The company has developed an innovative Semaglutide Injection (15 mg/3 ml) in a prefilled cartridge administered using a patient-friendly reusable pen for which the company has exclusive rights
Zydus launches biosimilar Aflibercept 2 mg ANYRA™ for advancing ophthalmic care
ANYRA™ is India’s first indigenously developed Aflibercept 2 mg biosimilar
Zydus launches PEPAIR, a first in India, affordable, drug-free, handheld device...
In a patient-centric approach, Zydus offers PEPAIR at an affordable cost of Rs. 990 per unit
Zydus Lifesciences reports strong Q3 and 9M FY26 financial performance
In Q3 FY26, revenue from operations rose 30% year-on-year to ₹68,645 million, while EBITDA grew 31% to ₹18,164 million, with margins improving to 26.5%
Zydus receives USFDA Orphan Drug Designation for Desidustat to treat Sickle...
Zydus’ NCE Desidustat is a hypoxia inducible factor (HIF)-prolyl hydroxylase inhibitor (PHI) and has the potential to increase haemoglobin and red blood cell counts
Zydus launches Tishtha, the world’s first biosimilar of Nivolumab, in India...
The immunotherapy reduces treatment burden by making it accessible at approximately 1/4th cost of the reference drug
Zydus, Formycon forge exclusive deal to license & supply Keytruda biosimilar...
The BLA application is expected to be submitted to the USFDA in the near future and is aimed at making immunotherapy affordable and accessible to patients in need
Zydus and Pinkathon unite to champion breast cancer awareness in Bengaluru
From 3 km community runs to 100 km ultras, Pinkathon 2025–26 will begin its Bengaluru chapter on January 25 at Sree Kanteerava Stadium, Bengaluru
Zydus’ Amplitude receives CE mark for its robotic surgical system ‘Andy’
Andy’s CE mark expands the EU market opportunity for Amplitude Surgical
Zydus receives USFDA Orphan Drug Designation for Desidustat for the treatment...
Orphan drug designation by the USFDA for Desidustat, provides eligibility for a potential seven-year marketing exclusivity subject to the USFDA approval